Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose

Journal of Gastroenterology

Volumn 32, Issue 6, 1997, Pages 777-782

  Kihara, Yasuyuki ^a   Ogami, Yoshimitsu ^a   Tabaru, Akinari ^a   Unoki, Hideaki ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Acarbose; Ammonia; Chronic liver diseases; Diabetes mellitus; Liver function

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; AMMONIA; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030732595     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02936954     Document Type: Article

References (30)

1. Clissold SP, Edwards C. Acarbose, preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988;35:214-243.
2. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition: A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977;64:536-537.
3. Puls W, Krause HP. Delay of carbohydrate absorption by inhibitors of intestinal alpha-glucosidases. Adv Exp Med Biol 1979; 119:341-346.
4. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-737.
5. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994;17:561-566.
6. Leonhardt W, Hanefeld M, Fischer S, et al. Efficacy of Éø-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidemia. Eur J Clin Invest 1994;24(Suple 3):45-49.
7. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver diseases. Lancet 1967;II:1051-1055.
8. Creutsfeld W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol. III. New York: Grune and Stratton, 1970:371-407.
9. Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: A review with some perspectives for the future. Diabetes Metab Rev 1989;5:691-709.
10. Del Vecchio Blanco C, Gentile S, Marmo R, et al. Alterations of glucose metabolism in chronic liver diseases. Diabetes Res Clin Pract 1990;8:29-36.
11. Gentile S, Loguercio C, Marmo R, et al. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract 1993;22:37-44.
12. Kingston ME, Ali MA, Atiyeh M, et al. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984;87: 688-694.
13. Samols E, Ryder J. Studies on tissue uptake of insulin in man using a differential immunoassay for endogenous and exogenous insulin. J Clin Invest 1961;40:2092-2102.
14. Petrides AS, Groop LC, Riely CA, et al. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991;88:561-570.
15. Müller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology 1992;102:2033-2041.
16. Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrohsis. Hepatology 1994;20:119-125.
17. Balfour JA, McTavish D, Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-1054.
18. Coniff RF, Shapiro JA, Timothy B, et al. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442-2448.
19. Pugh RNH, Murray-Layon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
20. Chuas KS, Tan IK. Plasma glucose measurement with the Yellow Springs Glucose Analyzer. Clin Chem 1978;24:470-475.
21. Cole RA, Soeldner JS, Dunn PJ, et al. A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography. Metabolism 1978;27:289-301.
22. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;2:470-475.
23. The Diabetes Control and Complications Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
24. Spengler M, Cagatay M. The use of acarbose in the primary-care setting: Evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin Invest Med 1995;18:325-331.
25. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995;18:817-824.
26. Andrade RJ, Lucena MI, Rodriguez-Mendizábal M. Hepatic injury caused by acarbose. Ann Intern Med 1996;124:931.
27. Zillikens MC, Swart GR, Van den Berg JWO, et al. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989;3:453-459.
28. Müting D. Acarbose bei der Behandlung von Diabetikern mit gleichzeitiger Leberzirrhose. Therapiewoche 1984;34:2566-2572.
29. Goto Y, Nakagawa S, Goto Y, et al. A double-blind study on the efficacy of BAY g 5421 (acarbose) in non-insulin dependent diabetes mellitus (NIDDM) (in Japanese). Igaku no Ayumi 1989; 149:591-618.
30. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-935.